Safety, tolerability, and seizure control during long-term treatment with adjunctive brivaracetam for partial-onset seizures

Grants

Funding Acknowledgements

This study was funded by UCB Pharma, which was involved in the design and conduct of the study; collection, management, and analysis of the data; and preparation and review of the manuscript. The authors acknowledge Mark Hughes and Sally Cotterill (QXV Comms, an Ashfield Business, part of UDG Healthcare plc, Macclesfield, United Kingdom) for writing assistance, which was funded by UCB Pharma.